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Antiretroviral regimen simplification improves quality of life and medication adherence while reducing the risk of HIV virologic
failure (VF) and long-term drug-related toxicities. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) is a well-
tolerated and efficacious once-daily single-tablet regimen (STR) treatment option. Here we report the Week 48 safety and
efficacy results of SPIRIT, the first study to evaluate switching from boosted protease inhibitor (PIRTV)-based HAART to a
simplified regimen of FTC/RPV/TDF STR. SPIRIT is a phase 3b, randomized, open-label, multi-center, international, 48-week study
to evaluate the safety and efficacy of switching from PIRTV regimens to FTC/RPV/TDF in virologically-suppressed HIV-1
infected participants. Participants were randomized 2:1 to switch to FTC/RPV/TDF at baseline or maintain their current PIRTV
regimen with a delayed switch to FTC/RPV/TDF at Week 24.The primary endpoint was non-inferiority (12% margin) of FTC/RPV/
TDF relative to PIRTV regimens in maintaining plasma HIV-1 RNAB50 copies/mL at Week 24 by FDA snapshot analysis. Plasma
HIV-1 RNA levels were assessed at screening, baseline, and at Weeks 4, 8, 12, 24, (28 and 32 for delayed switch participants), 36,
and 48 or early termination. A total of 476 participants were randomized and received at least 1 dose of study drug (317 FTC/
RPV/TDF; 159 PIRTV2NRTIs). Baseline characteristics were similar across treatment arms. The primary endpoint of
non-inferiority at Week 24 was met (HIV-1 RNA B50 copies/mL by FDA snapshot analysis 93.7% FTC/RPV/TDF vs. 89.9%
PIRTV2NRTIs; difference 3.8%, 95% CI: 1.6 to 9.1]). Through Week 48, 88.3% of subjects switching to FTC/RPV/TDF at
baseline maintained virologic suppression (HIV-1 RNAB50 copies/mL by FDA snapshot analysis). The rate of virologic
suppression at Week 48 for the 152 participants who switched to FTC/RPV/TDF at Week 24 was comparable to the rate of
virologic suppression at Week 24 for those who switched to FTC/RPV/TDF at baseline (delayed switch to FTC/RPV/TDF 92.1%;
baseline switch to FTC/RPV/TDF 93.7%). In the Week 48 analysis of SPIRIT, the first study to evaluate switching to FTC/RPV/TDF
STR from a PIRTV-based regimen in virologically-suppressed, HIV-1-infected participants, virologic suppression was maintained
regardless of whether participants switched to FTC/RPV/TDF at baseline or at Week 24.
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